Product
BNT162b3
1 clinical trial
2 indications
Indication
COVID-19Indication
Protection Against COVID-19Clinical trial
A Multi-site, Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of a Prophylactic SARS-CoV-2 RNA Vaccine (BNT162b3) Against COVID-19 Using Different Dosing Regimens in Healthy AdultsStatus: Completed, Estimated PCD: 2021-03-12